000169184 001__ 169184
000169184 005__ 20240229133644.0
000169184 0247_ $$2doi$$a10.1177/13524585211022011
000169184 0247_ $$2pmid$$apmid:34124961
000169184 0247_ $$2ISSN$$a1352-4585
000169184 0247_ $$2ISSN$$a1477-0970
000169184 0247_ $$2altmetric$$aaltmetric:107885498
000169184 037__ $$aDKFZ-2021-01308
000169184 041__ $$aEnglish
000169184 082__ $$a610
000169184 1001_ $$aWu, Jing$$b0
000169184 245__ $$aHigh antibody levels against human herpesvirus-6A interact with lifestyle factors in multiple sclerosis development.
000169184 260__ $$aLondon$$bSage$$c2022
000169184 3367_ $$2DRIVER$$aarticle
000169184 3367_ $$2DataCite$$aOutput Types/Journal article
000169184 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1648719667_24556
000169184 3367_ $$2BibTeX$$aARTICLE
000169184 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169184 3367_ $$00$$2EndNote$$aJournal Article
000169184 500__ $$a2022 Mar;28(3):383-392
000169184 520__ $$aInfection with human herpesvirus 6A (HHV-6A) has been suggested to increase multiple sclerosis (MS) risk. However, potential interactions between HHV-6A and environmental/lifestyle risk factors for MS have not previously been studied.We used two Swedish population-based case-control studies comprising 5993 cases and 5995 controls. Using logistic regression models, subjects with different HHV-6A antibody levels, environmental exposures, and lifestyle habits were compared regarding MS risk, by calculating odds ratios (ORs) with 95% confidence intervals (CIs). Potential interactions between high HHV-6A antibody levels and common environmental exposures and lifestyle factors were evaluated on the additive scale.High HHV-6A antibody levels were associated with increased risk of developing MS (OR = 1.5, 95% CI = 1.4-1.6). Regarding MS risk, significant interactions were observed between high HHV-6A antibody levels and both smoking (attributable proportion (AP) = 0.2, 95% CI = 0.1-0.3), low ultraviolet radiation (UVR) exposure (AP = 0.3, 95% CI = 0.1-0.4), and low vitamin D levels (AP = 0.3, 95% CI = 0.0-0.6).High HHV-6A antibody levels are associated with increased MS risk and act synergistically with common environmental/lifestyle risk factors for MS. Further research is needed to investigate potential mechanisms underlying the interactions presented in this study.
000169184 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000169184 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169184 650_7 $$2Other$$aMultiple sclerosis
000169184 650_7 $$2Other$$aenvironmental risk factors
000169184 650_7 $$2Other$$ahuman herpesvirus 6A
000169184 650_7 $$2Other$$ainteraction
000169184 7001_ $$aEngdahl, Elin$$b1
000169184 7001_ $$aGustafsson, Rasmus$$b2
000169184 7001_ $$aFogdell-Hahn, Anna$$b3
000169184 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b4$$udkfz
000169184 7001_ $$aHillert, Jan$$b5
000169184 7001_ $$aOlsson, Tomas$$b6
000169184 7001_ $$aAlfredsson, Lars$$b7
000169184 7001_ $$00000-0002-6612-4749$$aHedström, Anna Karin$$b8
000169184 773__ $$0PERI:(DE-600)2008225-3$$a10.1177/13524585211022011$$gp. 135245852110220 -$$n3$$p383-392$$tMultiple sclerosis journal$$v28$$x1477-0970$$y2022
000169184 909CO $$ooai:inrepo02.dkfz.de:169184$$pVDB
000169184 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000169184 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000169184 9130_ $$0G:(DE-HGF)POF3-316$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfections and cancer$$x0
000169184 9141_ $$y2021
000169184 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000169184 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000169184 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000169184 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2022-11-16$$wger
000169184 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMULT SCLER J : 2021$$d2022-11-16
000169184 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-16
000169184 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-16
000169184 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-16
000169184 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-16
000169184 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-16
000169184 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-16
000169184 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-16
000169184 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-16
000169184 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-16
000169184 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMULT SCLER J : 2021$$d2022-11-16
000169184 9201_ $$0I:(DE-He78)F022-20160331$$kF022$$lInfektionen und Krebs-Epidemiologie$$x0
000169184 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x1
000169184 980__ $$ajournal
000169184 980__ $$aVDB
000169184 980__ $$aI:(DE-He78)F022-20160331
000169184 980__ $$aI:(DE-He78)F020-20160331
000169184 980__ $$aUNRESTRICTED